CRIS - Earnings announcements

Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended March 31, 2026. Operational HighlightsTakeAim LymphomaEmavusertib is currently undergoing testing in combination with the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib in the TakeAim Lymphoma Phase 1/2 open-label, single arm expans

Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025. Operational HighlightsTakeAim LymphomaLakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL

LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio

LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2024. Operational Highlights TakeAim Lymphoma In July 2024, emavusertib was granted Orphan Drug Designation (ODD) by the European Commission (EC) for the treatment of patients with pr

LEXINGTON, Mass., July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

LEXINGTON, Mass., May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial 800-836-8184 from the United States or 646-357-8785 from other locations, shortly before 4:30 p.m. ET. The conference call can a

Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024. Operational Highlights The Company will release a topline update of clinical data from the ongoing TakeAim Leukemia study of emavusertib monotherapy in patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML

LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET. To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 8:30 a.m. ET. The conference call c

Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Feb. 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2023. Operational Highlights In December at the 65th American Society

LEXINGTON, Mass., Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its fourth quarter 2023 financial results on Thursday, February 8, 2024, at 8:00 a.m. ET. Management will host a conference call at 8:30 a.m. ET. To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locations, shortly before 8:30 a.m. ET. The conference call can also be

Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D. Academics and industry professionals will gather virtually on September 22, 2023 LEXINGTON, Mass., Sept. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced the 2nd Symposium on IRAK4 in Cancer taking place virtually on September 22, 9:00am-1:00pm ET. Hosted by Dr. Guillermo Garcia-Manero and Dr. Eric Winer, this symposium will

LEXINGTON, Mass., July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locat

Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Development Officer Strong balance sheet with $71.8 million in cash and investments; cash runway into 2025 Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., May 4, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the first quarter ended March 31, 2023.

LEXINGTON, Mass., April 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2023 financial results on Thursday, May 4, 2023, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can als

Curis completes enrollment of the 9 additional patients requested by FDA ahead of schedule in its TakeAim Leukemia study Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., March 13, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the fourth quarter ended December 31, 2022. As announced in November, the Company has concentrated its resources to focus on the development of emavusertib. As a

LEXINGTON, Mass., March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m. ET to Monday, March 13, 2023 at 8:30 a.m. ET.  The business update will be released at 8:00 a.m. ET on March 13, followed by an investor conference call hosted by management at 8:30 a.m. ET. To access the live conference call

LEXINGTON, Mass., March 2, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2022 financial results on Thursday, March 9, 2023, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can a

29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to review results during conference call, featuring commentary by Dr. Eric Winer, MD, Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1a dose escalation study of emavusertib (CA-4948), a novel, small molecule IRAK-4 inhib

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a webcast on Monday, December 12, 2022, at 10:00 a.m. ET to discuss new data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting.

Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended into 2025 Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 9, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the third quarter ended September 30, 2022. The Company plans to release upda

LEXINGTON, Mass., Nov. 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can

Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.; Amit Verma, M.B.B.S. Academics and industry professionals will gather virtually on October 7, 2022 LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the 1st Symposium on IRAK4 in Cancer taking place virtually on October 7, 9:00am-1:00pm ET. Hosted by Drs. Guillermo Garcia-Manero, Hagop Kantarjian, and Amit Verma, this symposium will focus on IRAK4, an essenti

Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the 2nd Annual VISTA Symposium will take place virtually on September 23, 9:00am-1:00pm ET. The event will be hosted by Randolph Noelle, Ph.D., Active Emeritus Professor of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of M

Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) Appointed Industry Veteran Diantha Duvall as Chief Financial Officer Strong balance sheet with $107.2 million in cash and investments as of June 30, 2022; cash runway into 2024 Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., Aug. 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f

LEXINGTON, Mass., July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 pm ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET. The conference call can also

Strong balance sheet with $120.7 million in cash and investments at March 31, 2022; no change to cash guidance: cash runway into 2024 Potential opportunity for emavusertib in pancreatic cancer highlighted in a publication from Washington University in St. Louis Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., May 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2022 and provided business updates.

LEXINGTON, Mass., April 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 pm ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317- 5252 from other locations, shortly before 4:30 pm ET. The conference call can also b

LEXINGTON, Mass., Feb. 24, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter ended December 31, 2021. "2021 was a year marked by significant clinical progress across our pipeline of targeted cancer therapies, including our report of positive updated data from our ongoing Phase 1/2 TakeAim Leukemia study of emavusertib (CA-4948) demonstrating a favorable safety profile and encouraging anti-cancer activity, with expa

LEXINGTON, Mass., Feb. 17, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 pm ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317- 5252 from other locations, shortly before 4:30 pm ET. The conference call can

LEXINGTON, Mass., Jan. 6, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948, a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) as well as initial safety, pharmacokinetic and pharmacodynamic data from the Phase 1 dose escalation study of CI-8993, a monoclonal antibody targeting VISTA for patients with R/R solid tumors.

LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2021 and provided business updates. "During the third quarter of 2021, we continued to advance our clinical trials of CA-4948, our first-in-class, small molecule IRAK4 inhibitor in nine distinct patient populations across AML, MDS and B cell cancers, including the recent initiation of our Phase 1 combination study in AML/

LEXINGTON, Mass., Nov. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 pm ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET. The conference call can also

LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2021. "In the second quarter of 2021, we continued executing on planned milestones across our pipeline of next generation targeted cancer therapies designed to meaningfully improve and extend patients' lives. We drove important progress with our first-in-class, small molecule IRAK4 inhibitor CA-4948, expanding our clinical tr

LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2021 financial results on Tuesday, August 3, 2021, after the close of US markets. Management will host a conference call on the same day at 4:30 pm ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET. The conference call can also be